Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HMGCR | P04035 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | ACLY | P53396 | 3/20 | 0.39 |
| ▸ | CPT2 | P23786 | 1/20 | 0.38 |
| ▸ | TET2 | Q6N021 | 2/20 | 0.33 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7127403 | 0.97 | ALDH1A1 (0.46) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL28555973 | 0.97 | ALDH1A1 (0.46) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL95160 | 0.83 | ALDH1A1 (0.58) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL27466021 | 0.80 | ALDH1A1 (0.55) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL5085109 | 0.75 | ALDH1A1 (0.44) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL27554101 | 0.75 | ALDH1A1 (0.44) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL493898 | 0.74 | ALDH1A1 (0.48) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL28576099 | 0.72 | ALDH1A1 (0.46) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL723552 | 0.72 | ALDH1A1 (0.41) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL723551 | 0.72 | ALDH1A1 (0.41) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113367159-A | Composite biological bactericide and application thereof | 中诚国联（河南）生物科技有限公司 | 2021-09-10 | — | — | CN | claimed |
| EP-2468847-B1 | EUKARYOTIC MICROORGANISMS FOR PRODUCING LIPIDS AND ANTIOXIDANTS | DSM NUTRITIONAL PRODUCTS AG (CH) | 2017-03-29 | — | — | EP | claimed |
| EP-2951285-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF PATHOGENIC BACTERIAL GROWTH | Seres Therapeutics, Inc. (US) | 2015-12-09 | — | — | EP | claimed |
| WO-2014121301-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF PATHOGENIC BACTERIAL GROWTH | Seres Health, Inc. (US) | 2014-08-07 | — | — | WO | claimed |
| US-20130344546-A1 | EUKARYOTIC MICROORGANISMS FOR PRODUCING LIPIDS AND ANTIOXIDANTS | OCEAN NUTRITION CANADA, LTD. (CA) | 2013-12-26 | — | — | US | claimed |
| US-20130225663-A1 | LIPID DELIVERY FORMULATIONS | DICERNA PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | claimed |
| WO-2011109294-A1 | LIPID DELIVERY FORMULATIONS | DICERNA PHARMACEUTICALS, INC. (US) | 2011-09-09 | — | — | WO | claimed |
| EP-1501938-B1 | ANALYSIS OF SUBSTRATE UTILIZATION BY ANIMAL OR PLANT CELLS | BIOLOG INC (US) | 2009-10-21 | — | — | EP | claimed |
| EP-1501938-A4 | COMPARATIVE PHENOTYPE ANALYSIS OF CELLS, INCLUDING TESTING OF BIOLOGICALLY ACTIVE COMPOUNDS | BIOLOG INC (US) | 2007-01-03 | — | — | EP | claimed |
| EP-1501938-A2 | COMPARATIVE PHENOTYPE ANALYSIS OF CELLS, INCLUDING TESTING OF BIOLOGICALLY ACTIVE COMPOUNDS | BIOLOG, INC. (US) | 2005-02-02 | — | — | EP | claimed |
| WO-2003089652-A2 | COMPARATIVE PHENOTYPE ANALYSIS OF CELLS, INCLUDING TESTING OF BIOLOGICALLY ACTIVE COMPOUNDS | BIOLOG, INC. (US) | 2003-10-30 | — | — | WO | claimed |
| US-20030162164-A1 | Comparative phenotype analysis of cells, including testing of biologically active compounds | BIOLOG, INC. | 2003-08-28 | — | — | US | claimed |
| US-6569986-B1 | Multistage process; using tetraalkylphosphonium compound and basic catalyst | GENERAL ELECTRIC COMPANY | 2003-05-27 | — | — | US | claimed |
| EP-4676500-A2 | MICROBIAL CONSORTIA | Kanvas Biosciences, Inc (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20260007704-A1 | MICROBIAL CONSORTIA | Kanvas Biosciences, Inc. (US) | 2026-01-08 | — | — | US | disclosed |
| US-12507703-B2 | Methods, devices and compositions for preserving human milk | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2025-12-30 | — | — | US | disclosed |
| WO-1997016562-A1 | METHODS FOR REMOVING INTERFERENCES DUE TO ENDOGENOUS DEHYDROGENASES IN ENZYME ASSAYS | DADE BEHRING MARBURG GMBH (DE) | 1997-05-09 | — | — | WO | disclosed |
| CN-1108873-A | A method of tree protection | BAYER AGROCHEM KK (JP) | 1995-09-27 | — | — | CN | disclosed |
| US-5374304-A | Modifyig with formamide and dichloroacetic acid; casting films and sheets mixed with plasticizer; flexible, transparent | BATTELLE-INSTITUT E.V. (DE) | 1994-12-20 | — | — | US | disclosed |
| EP-0564945-A1 | A method of controlling harmful insects | NIHON BAYER AGROCHEM K.K. (JP) | 1993-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007704-A1 | MICROBIAL CONSORTIA | ALPI, FABP2, SI | ALDH1A1 1308/4885HMGCR 1789/4885CHRM1 2811/4885 |
| US-12507703-B2 | Methods, devices and compositions for preserving human milk | LPL, CEL, LPO | ALDH1A1 1545/4885HMGCR 562/4885CHRM1 1467/4885 |
| US-20130225663-A1 | LIPID DELIVERY FORMULATIONS | LIPA, LIPC, CETP | ALDH1A1 3881/4885HMGCR 116/4885CHRM1 4796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.